about
Antipsychotic medications for cocaine dependenceAnticonvulsants for cocaine dependenceAnticonvulsants for cocaine dependenceDopamine agonists for the treatment of cocaine dependenceAnticonvulsants for alcohol dependenceQTc interval screening for cardiac risk in methadone treatment of opioid dependenceDopamine agonists for the treatment of cocaine dependenceAntidepressants for cocaine dependence and problematic cocaine useAntidepressants for the treatment of depression in alcohol dependent individualsAnticonvulsants for alcohol dependenceECG screening for preventing long QTc-related cardiac morbidity/mortality in methadone treated opioid addictsPharmacological treatment for depression during opioid agonist treatment for opioid dependencePharmacological treatment for depression in opioid dependenceDisulfiram for the treatment of cocaine dependenceAnticonvulsants for cocaine dependenceDisulphiram for the treatment of cocaine dependenceAntipsychotic medications for cocaine dependenceEfficacy of Medications Approved for the Treatment of Alcohol Dependence and Alcohol Withdrawal Syndrome in Female Patients: A Descriptive ReviewSubtyping patients with heroin addiction at treatment entry: factor derived from the Self-Report Symptom Inventory (SCL-90).Psychopathological symptoms of patients with heroin addiction entering opioid agonist or therapeutic community treatment.Long-term γ-hydroxybutyric acid (GHB) and disulfiram combination therapy in GHB treatment-resistant chronic alcoholics.Harm Reduction as "Continuum Care" in Alcohol Abuse Disorder.The mental status of 1090 heroin addicts at entry into treatment: should depression be considered a 'dual diagnosis'?Psychopathology of addiction: May a SCL-90-based five dimensions structure be applied irrespectively of the involved drug?Delineating the psychic structure of substance abuse and addictions: should anxiety, mood and impulse-control dysregulation be included?Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients.Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts?Buprenorphine: a controlled clinical trial in the treatment of opioid dependence.Alcohol and cocaine use and abuse among opioid addicts engaged in a methadone maintenance treatment program.Use of street methadone in italian heroin addicts presenting for opioid agonist treatment.The long-term outcomes of heroin dependent-treatment-resistant patients with bipolar 1 comorbidity after admission to enhanced methadone maintenance.Effect of psychiatric severity on the outcome of methadone maintenance treatment.Is the bipolar spectrum the psychopathological substrate of suicidality in heroin addicts?Gamma-hydroxybutyric acid for treatment of opiate withdrawal syndrome.Towards a unitary perspective between post-traumatic stress disorder and substance use disorder. Heroin use disorder as case study.Long-term outcomes of treatment-resistant heroin addicts with and without DSM-IV axis I psychiatric comorbidity (dual diagnosis).Psychiatric severity and treatment response in a comprehensive methadone maintenance treatment program.Prohibition of take-home dosages: negative consequences on methadone maintenance treatment.Psychic Structure of Opioid Addiction
P50
Q24186021-5FB01336-AB88-4DF5-AAEC-4EAA9AAF5DA7Q24186475-E929EC5B-50A1-434A-A2BA-57DDC99DDC5EQ24187487-54FF5ED8-F3B5-42A3-9CB0-3E34A7056BE6Q24187799-D917D9C9-5A6A-4902-B0F2-C5DED3E96F11Q24200396-4F132F10-8558-4025-808A-8FFACA05D137Q24201880-D1246C4B-35F3-4CFE-9FD7-5162A0DEC7A9Q24234240-EA4094B4-39FD-406D-B625-480F3BCC9CFDQ24234248-C5371AEC-33DB-43CF-B07A-1CD75312B61EQ24234481-7FE32D96-F234-4ABD-AB06-A3FE14BD9882Q24235085-4FF480BD-3473-40E2-B3C2-6B67CF44AD16Q24235379-B14B2462-9CA0-41C9-AA68-3E4C8F34C5ADQ24235458-AEAD32C2-B3A8-4E65-A980-60B8666CBEABQ24240200-1D271B5E-A339-4EB8-A027-27E028A38A9DQ24240796-CBA6982B-29D5-4521-B9B2-333DB079D0D4Q24242962-D50BAC07-1820-41F8-AE5A-24F8BDBDFC4CQ24243366-286B1E9F-FC07-40F0-80A8-46312C21D334Q24243837-836E74E6-B328-4C99-8E72-545B8AB55247Q26796541-7F336CE3-E9AE-450D-9F8B-7FEE591E4F77Q33818659-4512E0FE-C3CF-457E-A80E-1ECAEB20AC1DQ34586382-C136E246-FAB7-4E2C-B5D9-6143F408754CQ35162034-5ED3162C-6AC0-4D52-9A82-E5E99131ECABQ36324239-566246EC-9004-40E4-B886-5C677A025097Q36409749-175475AD-E57F-463F-A576-9FCCD7A6A939Q36836847-B75C8E54-6B6E-4316-AAFF-48C29F33610DQ37543722-D117275E-3472-457F-B6FD-DAA26A703F60Q42624418-135F7277-616D-405F-8D5B-53423A7FE421Q42754294-98569991-9F98-450D-8E27-38DA187860E6Q44331745-DD6AC633-E904-490F-90AC-D46E8DF5A328Q44334747-062DA5ED-D49C-4609-A15C-A7FD06678609Q44345468-9D6B7860-AD18-4023-A6B2-12DD1595B555Q44457285-A601A854-DC75-41F8-81D9-5420968B062EQ48302941-255DECFF-C2C1-4413-AA7C-F6FDE21BCB16Q50894783-009D38F1-09B4-4DBC-9C14-7AAF428ADEF3Q51658733-7051E868-3C0F-4F7D-A2D0-E32A4DD1E558Q51838969-65037B21-DFD7-4949-8226-A034B2AF3092Q51889746-5AD61CF3-8DC0-4E9C-8C95-1B4B092D4675Q52275542-748FB3DE-000C-4FEB-9BDB-73C37960E585Q52909477-E9FB712F-14ED-458C-94F5-3AB36D2E68E4Q57209624-BDD5FA58-A498-472E-AA0A-93F3F8265652
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pier Paolo Pani
@ast
Pier Paolo Pani
@en
Pier Paolo Pani
@es
Pier Paolo Pani
@fr
Pier Paolo Pani
@nl
Pier Paolo Pani
@sl
type
label
Pier Paolo Pani
@ast
Pier Paolo Pani
@en
Pier Paolo Pani
@es
Pier Paolo Pani
@fr
Pier Paolo Pani
@nl
Pier Paolo Pani
@sl
prefLabel
Pier Paolo Pani
@ast
Pier Paolo Pani
@en
Pier Paolo Pani
@es
Pier Paolo Pani
@fr
Pier Paolo Pani
@nl
Pier Paolo Pani
@sl
P1053
K-1353-2016
P106
P1153
55793475500
7006339176
P21
P31
P3829
P496
0000-0001-5969-1342
P569
2000-01-01T00:00:00Z